In Vitro Efficacy Testing Services for Kidney Fibrosis

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Kidney Fibrosis. Our service enables precise assessment of candidate compounds targeting key mediators involved in renal fibrogenesis, such as transforming growth factor-beta (TGF-β), extracellular matrix (ECM) components, and inflammatory pathways. We focus on evaluating molecular mechanisms underlying fibroblast activation, ECM deposition, and cytokine signaling implicated in progressive kidney fibrosis. Through these assays, we support the identification and optimization of novel therapeutics aimed at halting or reversing fibrotic processes in kidney disease.

Our testing portfolio includes a comprehensive range of biochemical, enzymatic, receptor-binding, and cell-based assays. These methods are designed to evaluate compound efficacy, target engagement, and mechanistic pathways relevant to kidney fibrosis. By leveraging advanced detection technologies, we provide reliable data to guide preclinical drug development.

20-HETE formation assay: Measures the synthesis of 20-hydroxyeicosatetraenoic acid, a key regulator of renal vascular tone and fibrosis, providing insights into enzymatic activity and pathway modulation.

ATP assay: Quantifies cellular ATP levels to assess cell viability and metabolic status following compound treatment, indicating cytotoxic or protective effects.

Arachidonic acid as substrate: Utilizes arachidonic acid in enzymatic assays to analyze pathway activity relevant to eicosanoid-mediated fibrosis mechanisms.

Bioluminescence resonance energy transfer (BRET) assay: Detects protein-protein or ligand-receptor interactions in live cells, enabling monitoring of receptor activation and signaling events.

Chemiluminescent assay: Employs chemiluminescence for sensitive detection of specific biomolecules or enzyme activities associated with fibrotic progression.

Displacement of [125I]-AB-MECA: Evaluates compound binding affinity for adenosine receptors by measuring displacement of radiolabeled ligand, crucial for receptor-targeted therapies.

ELISA assay: Quantifies proteins, cytokines, or growth factors implicated in fibrosis using antibody-based detection, facilitating biomarker analysis.

Fluorescence resonance energy transfer (FRET) assay: Monitors molecular interactions or conformational changes in real time, supporting pathway analysis in fibrogenesis.

Fluorescent assay: Uses fluorescent probes to measure cellular or molecular responses, including enzyme activity and signal transduction.

Luciferine/luciferase assay: Detects gene expression or cellular activity via light emission, often applied in promoter activity or cell viability studies.

RNA assay: Measures gene expression changes linked to fibrotic markers, allowing assessment of transcriptional responses to therapeutic agents.

Surface plasmon resonance assay: Provides real-time, label-free analysis of biomolecular interactions, particularly for quantifying binding kinetics and affinities.

cAMP accumulation assay: Assesses intracellular cyclic AMP levels to evaluate receptor-mediated signaling pathways involved in kidney fibrosis.

We measure a range of pharmacological parameters including potency, affinity, and inhibitory effects to thoroughly characterize compound activity. These metrics are essential for comparing candidate drugs and optimizing lead selection for progression into in vivo studies. Accurate parameter determination supports decision-making in early-stage drug development.

EC-50: The concentration of a compound that produces 50% of its maximal effect, indicating compound potency and used for dose-response assessments.

IC-50: The concentration required to inhibit a specific biological or biochemical function by 50%, reflecting inhibitory strength of a candidate.

Kb: The equilibrium dissociation constant for antagonists, important for quantifying antagonist-receptor interactions.

Kd: The equilibrium dissociation constant reflecting binding affinity between ligand and target, crucial for evaluating molecular interactions.

Ki: The inhibition constant representing binding affinity of an inhibitor, aiding in the comparison of inhibitor effectiveness.

MIC: Minimum inhibitory concentration needed to suppress a biological process, useful for determining effective dosing thresholds.

Recommended In Vitro Efficacy Tests

Adenosine A3 Receptor

Our Adenosine A3 Receptor testing service supports fibrosis and kidney drug development by assessing compounds targeting this receptor, which plays a key role in regulating inflammation and fibrotic processes. Using cAMP accumulation assays and [125I]-AB-MECA displacement, we determine compound potency and receptor binding. Main parameters measured include Ki (binding affinity), Kb (antagonist potency), and EC-50 (functional efficacy), providing comprehensive data for candidate evaluation.

Arachidonate 5-Lipoxygenase

Arachidonate 5-Lipoxygenase (5-LOX) plays a key role in pro-inflammatory mediator production linked to kidney fibrosis. Testing 5-LOX activity, using arachidonic acid as a substrate, is crucial in kidney fibrosis drug development to identify effective inhibitors. The primary parameter measured is IC-50, indicating inhibitor potency. This service enables precise assessment of candidate compounds targeting 5-LOX-mediated fibrosis pathways.

Bromodomain Containing 4

The Bromodomain Containing 4 (BRD4) protein regulates gene expression linked to fibrosis progression in kidney disease. Testing BRD4 inhibitors is crucial for developing targeted antifibrotic therapies. Our service utilizes Bioluminescence Resonance Energy Transfer (BRET) and fluorescent assays to assess inhibitor efficacy. The primary parameter measured is IC-50, indicating compound potency, enabling rapid and reliable screening of drug candidates for kidney fibrosis treatment.

Cellular Communication Network Factor 2

Cellular Communication Network Factor 2 (CCN2) is a key mediator of fibrosis in kidney disease, promoting extracellular matrix accumulation and tissue scarring. Testing CCN2 expression is crucial for evaluating anti-fibrotic drug efficacy in kidney drug development. Our service utilizes sensitive RNA assays to quantify CCN2 mRNA levels, providing critical data on drug impact. The main parameter assessed is the minimum inhibitory concentration (MIC), reflecting compound potency in reducing CCN2 expression.

Cytochrome P450 Family 4 Subfamily A Member 11

Cytochrome P450 Family 4 Subfamily A Member 11 (CYP4A11) regulates 20-HETE synthesis, impacting renal fibrosis and kidney function. Testing CYP4A11 activity is vital for kidney drug development targeting fibrosis pathways. Our service utilizes the 20-HETE formation assay to assess enzyme function, providing IC-50 values for compound inhibition. This enables precise evaluation of drug candidates’ effects on CYP4A11-mediated pathways, accelerating discovery of effective kidney therapeutics.

Cytochrome P450 Family 4 Subfamily F Member 2

Cytochrome P450 Family 4 Subfamily F Member 2 (CYP4F2) regulates 20-HETE synthesis, impacting fibrosis and kidney function. Testing CYP4F2 activity is essential for kidney drug development, as altered 20-HETE levels are linked to fibrotic progression. The 20-HETE formation assay quantifies enzyme inhibition, with IC50 as the main parameter, enabling precise assessment of compound efficacy in modulating CYP4F2 activity for antifibrotic therapies.

Delta 4-Desaturase, Sphingolipid 1

Delta 4-Desaturase, Sphingolipid 1 is implicated in kidney fibrosis by modulating sphingolipid metabolism, influencing fibrotic signaling pathways. Testing its activity is vital for drug development targeting fibrosis. Key methods include enzyme assays and LC-MS/MS-based sphingolipid profiling. Main parameters measured are enzyme activity levels, sphingolipid species concentrations, and biomarker changes, providing crucial insights for evaluating therapeutic efficacy in kidney fibrosis models.

Discoidin Domain Receptor Tyrosine Kinase 1

Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) mediates collagen signaling, promoting fibrosis in kidney disease. DDR1 testing is crucial for evaluating anti-fibrotic drug efficacy and target engagement in renal drug development. We offer advanced assays, including surface plasmon resonance, BRET, FRET, chemiluminescent, ATP, and ELISA assays, quantifying key parameters such as Kd and IC50 to assess binding affinity and inhibitory potency of candidate compounds.

Epoxide Hydrolase 2

Epoxide Hydrolase 2 (EH2) regulates lipid signaling implicated in kidney fibrosis progression. EH2 testing is vital for evaluating drug efficacy and safety during fibrosis-targeted kidney drug development. Key methods include enzyme activity assays and quantitative PCR for EH2 expression. Main parameters measured are EH2 enzymatic activity, mRNA/protein levels, and response to candidate compounds, supporting mechanism-based therapeutic screening and biomarker-driven decisions.

Homeodomain Interacting Protein Kinase 2

Homeodomain Interacting Protein Kinase 2 (HIPK2) regulates pathways implicated in kidney fibrosis progression. Testing HIPK2 activity is crucial for identifying and optimizing therapeutics targeting renal fibrosis. Our service utilizes a luciferin/luciferase assay to accurately measure HIPK2 inhibition, providing precise IC-50 values for drug candidates. This enables efficient screening and development of novel anti-fibrotic agents for kidney disease.